Influenzavirus B Infections Therapeutic and Drug Pipeline Review H2

Influenzavirus B Infections Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, September 15, 2017 /EINPresswire.com/ -- Pune, India, 15th September 2017: WiseGuyReports announced addition of new report, titled “Influenzavirus B Infections - Pipeline Review, H2 2017”.

Summary
Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2258219-influenzavirus-b-infections-pipeline-review-h2-2017

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 15, 2, 3, 9 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 2, 1 and 2 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Influenzavirus B Infections - Overview
Influenzavirus B Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenzavirus B Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenzavirus B Infections - Companies Involved in Therapeutics Development
AbbVie Inc
Adimmune Corp
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioCryst Pharmaceuticals Inc
Cadila Healthcare Ltd
ContraFect Corp
Daiichi Sankyo Company Ltd
Fujifilm Holdings Corporation
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2258219-influenzavirus-b-infections-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here